🇺🇸 FDA

Company profile · Sponsor

Jade

Jade Biosciences

JBIO · NYSE pharma WALTHAM, MA, USA
Pipeline
4
Drugs
0
Patents
2

Quick answer

Jade (JBIO) is a pharma company. headquartered in WALTHAM, MA, USA. listed on NYSE. NovaPharmaNews links 4 pipeline programs, 0 drugs, and 2 patents to this profile..

Company facts

Ticker JBIO
Exchange NYSE
Company type pharma
Headquarters WALTHAM, MA, USA
SEC CIK 0001798749

Pipeline (4)

Search pipeline →

  1. JADE101

    Jade

    IgA Nephropathy

    phase 2 small molecule active

    1 trial

  2. JADE101

    Jade

    Healthy Volunteers

    phase 1 small molecule active

    1 trial

  3. JADE101

    Jade

    Healthy Volunteers (HV)

    phase 1 small molecule active

    1 trial

  4. JADE201

    Jade

    Rhematoid Arthritis

    phase 1 small molecule active

    1 trial

Patents (2)

Search patents →

  1. US 9782345

    Ocular composition and method

    Expires Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 6149891

    X-ray contrast medium and method for protecting against harmful effects thereof

    Expires Mon Nov 16 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

What is Jade?

Jade (JBIO) is a pharma company. headquartered in WALTHAM, MA, USA. listed on NYSE. NovaPharmaNews links 4 pipeline programs, 0 drugs, and 2 patents to this profile..

What pipeline programs does Jade sponsor?

We track 4 ClinicalTrials.gov-linked programs for Jade, including JADE101 and 3 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Jade company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.